SG11202003967PA - Compositions comprising alpha-polyglutamic acid-zinc for treating cancer - Google Patents
Compositions comprising alpha-polyglutamic acid-zinc for treating cancerInfo
- Publication number
- SG11202003967PA SG11202003967PA SG11202003967PA SG11202003967PA SG11202003967PA SG 11202003967P A SG11202003967P A SG 11202003967PA SG 11202003967P A SG11202003967P A SG 11202003967PA SG 11202003967P A SG11202003967P A SG 11202003967PA SG 11202003967P A SG11202003967P A SG 11202003967PA
- Authority
- SG
- Singapore
- Prior art keywords
- alpha
- zinc
- compositions
- treating cancer
- polyglutamic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201708886RA SG10201708886RA (en) | 2017-10-30 | 2017-10-30 | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
PCT/SG2018/050544 WO2019088919A1 (en) | 2017-10-30 | 2018-10-29 | Compositions comprising alpha-polyglutamic acid-zinc for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003967PA true SG11202003967PA (en) | 2020-05-28 |
Family
ID=64184154
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201708886RA SG10201708886RA (en) | 2017-10-30 | 2017-10-30 | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
SG11202003967PA SG11202003967PA (en) | 2017-10-30 | 2018-10-29 | Compositions comprising alpha-polyglutamic acid-zinc for treating cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201708886RA SG10201708886RA (en) | 2017-10-30 | 2017-10-30 | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
Country Status (7)
Country | Link |
---|---|
US (1) | US20200254013A1 (en) |
EP (1) | EP3703708A1 (en) |
JP (1) | JP7352541B2 (en) |
KR (1) | KR20200080271A (en) |
CN (1) | CN111542328A (en) |
SG (2) | SG10201708886RA (en) |
WO (1) | WO2019088919A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
JP2024510327A (en) | 2021-03-18 | 2024-03-06 | ジロニックス・ピーティーイー.リミテッド | Pharmaceutical polymer conjugates |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
WO2001046110A2 (en) * | 1999-12-23 | 2001-06-28 | The University Of Georgia Research Foundation, Inc. | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
US20020061599A1 (en) * | 1999-12-30 | 2002-05-23 | Elling Christian E. | Method of identifying ligands of biological target molecules |
US8168657B2 (en) * | 2002-01-25 | 2012-05-01 | Bowen J Phillip | Solenopsin A, B and analogs and as novel angiogenesis inhibitors |
CN103735560A (en) * | 2005-06-07 | 2014-04-23 | 耶鲁大学 | Methods of treating cancer and other conditions or disease states using lfmau and ldt |
WO2007043606A1 (en) * | 2005-10-12 | 2007-04-19 | Genolac Bl Corporation | Antidiabetic agent comprising anionic polyamino acid-metal complex |
US20080253969A1 (en) * | 2007-04-10 | 2008-10-16 | Nitto Denko Corporation | Multi-functional polyglutamate drug carriers |
WO2008141110A2 (en) | 2007-05-09 | 2008-11-20 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
BRPI0811557A2 (en) * | 2007-05-09 | 2019-09-24 | Salutria Pharmaceuticals Llc | compound, pharmaceutical composition, method of treatment or prophylaxis of an inflammatory condition. |
US20110117210A1 (en) * | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
US9132098B2 (en) | 2013-03-28 | 2015-09-15 | Bbs Nanotechnology Ltd. | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it |
JP6262334B2 (en) | 2013-04-26 | 2018-01-17 | 日東電工株式会社 | Large scale method for producing poly (glutamyl-glutamate) conjugates |
SG10201609131YA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
-
2017
- 2017-10-30 SG SG10201708886RA patent/SG10201708886RA/en unknown
-
2018
- 2018-10-29 SG SG11202003967PA patent/SG11202003967PA/en unknown
- 2018-10-29 KR KR1020207014679A patent/KR20200080271A/en not_active Application Discontinuation
- 2018-10-29 CN CN201880084765.4A patent/CN111542328A/en active Pending
- 2018-10-29 EP EP18799880.2A patent/EP3703708A1/en active Pending
- 2018-10-29 JP JP2020522999A patent/JP7352541B2/en active Active
- 2018-10-29 US US16/760,264 patent/US20200254013A1/en active Pending
- 2018-10-29 WO PCT/SG2018/050544 patent/WO2019088919A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3703708A1 (en) | 2020-09-09 |
KR20200080271A (en) | 2020-07-06 |
US20200254013A1 (en) | 2020-08-13 |
JP2021501143A (en) | 2021-01-14 |
CN111542328A (en) | 2020-08-14 |
WO2019088919A1 (en) | 2019-05-09 |
JP7352541B2 (en) | 2023-09-28 |
SG10201708886RA (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267247B (en) | Compositions and methods for treating cancer | |
IL269150A (en) | Compositions and methods for treating cancer | |
PL3431105T3 (en) | Medicinal composition for treating cancer | |
HK1251407A1 (en) | Methods for treating cancer | |
IL304820A (en) | Compositions and methods for treating cancer | |
RS63561B1 (en) | Composition for treating cancer | |
IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
SG11201705093UA (en) | Composition for treating il-6-related diseases | |
IL269157A (en) | Compositions and methods for treating cancer | |
IL256523A (en) | Compositions and methods for treating cancer | |
HK1250944A1 (en) | Methods for treating cancer | |
SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
HK1250942A1 (en) | Methods for treating cancer | |
SG11202010528XA (en) | Combinations for treating cancer | |
HK1250943A1 (en) | Methods for treating cancer | |
IL255638A (en) | Compositions and methods for treating cancer | |
SG11202003967PA (en) | Compositions comprising alpha-polyglutamic acid-zinc for treating cancer | |
IL272782A (en) | Compositions and methods for treating cancer | |
ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
ZA201707024B (en) | Cancer treatment composition | |
EP3268028A4 (en) | Compositions and methods for treating cancer | |
HK1250958A1 (en) | Compositions and methods for treating cancer | |
IL255167A0 (en) | Compositions for the treatment of cancer | |
AU2022231657A1 (en) | Compositions and Methods for Treating Cancer | |
IL268715A (en) | Compositions for treating acne |